What Crinetics Pharmaceuticals does

Crinetics Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 and publicly traded on NASDAQ under ticker CRNX. The company develops and commercializes small molecule, selectively-targeted nonpeptide agonists and antagonists that address G-protein coupled receptors (GPCRs), with a strategic focus on rare endocrine diseases and endocrine-related tumors. Its core technology is a proprietary GPCR discovery engine that has produced 10+ disclosed pipeline programs targeting receptors including somatostatin receptor 2 (SST2), melanocortin receptor 2 (MC2R), TSH, PTH, SST3, GH, GLP-1, and GIP. The lead commercial product is PALSONIFY (paltusotine), the first and only once-daily oral SST2 agonist approved by the FDA (September 2025) and the European Commission (April 2026) for adults with acromegaly who had inadequate response to or are not candidates for surgery. Late-stage pipeline includes atumelnant (CRN04894), a first-in-class once-daily oral ACTH receptor antagonist in Phase 3 for classic congenital adrenal hyperplasia and Phase 1/2b for ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate in Phase 1/2 for SST2-expressing neuroendocrine tumors. The company has raised over $1.75 billion cumulatively, with $1.3 billion in cash and a stated runway into 2030.

Crinetics generates revenue primarily through product sales of PALSONIFY in the United States and, as of mid-2026, in the European Union, with additional de minimis collaboration and license revenue. Distribution operates through a specialty pharmacy model via partnerships with Orsini Healthcare (lead specialty pharmacy) and Biologics, supplemented by the company-operated CrinetiCARE patient support program and direct dispensing relationships with pituitary treatment centers. Pricing is not publicly disclosed. Q1 2026 total revenue was $10.7 million, including $10.3 million in PALSONIFY net product sales, representing sequential growth from $6.2 million in Q4 2025 and over 2,200% year-over-year growth off a small base. By end of Q1 2026, 263 unique healthcare providers had prescribed PALSONIFY, with approximately 70% of patients on reimbursed therapy. Geographic expansion is underway with Marketing Authorization Applications submitted in Brazil (March 2026) and Japan (April 2026 via partner SKK). The company is unprofitable, reporting a Q1 2026 net loss of $127.8 million and guiding to 2026 GAAP operating expenses of $600-650 million.

Name

Crinetics Pharmaceuticals

Legal name

Crinetics Pharmaceuticals, Inc.

Website

https://crinetics.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing oral, small molecule GPCR-targeted therapies for rare endocrine diseases. Its lead product PALSONIFY (paltusotine) is the first once-daily oral therapy approved for acromegaly, with a pipeline including atumelnant for CAH and CRN09682 for neuroendocrine tumors.

Ownership category

akta.pro rank

Product category

Endocrinology Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Rare endocrine therapeutics
• Oral somatostatin agonists
• GPCR small molecules
• Acromegaly treatment
• Specialty endocrinology pharmaceuticals

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. PALSONIFY Product Sales: Crinetics generates revenue through commercial sales of PALSONIFY (paltusotine) in the United States and European Union for treatment of acromegaly. Q1 2026 net product revenue was $10.3 million, up from $5.4 million in Q4 2025. The company also received EU approval in April 2026 with planned launch in Germany and Austria, and has submitted applications in Brazil and Japan.
2. Collaboration and License Revenue: The company generates minimal collaboration and license revenue, reported as $428,000 in Q1 2026 compared to $361,000 in Q1 2025.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Crinetics Pharmaceuticals discovers, develops, and commercializes novel small molecule therapies for rare endocrine diseases and endocrine-related tumors. Its first commercial product, PALSONIFY (paltusotine), is an oral once-daily SST2 agonist approved in the US (September 2025) and EU (April 2026) for acromegaly. The pipeline includes atumelnant (oral ACTH antagonist for CAH and Cushing's syndrome) and CRN09682 (nonpeptide drug conjugate for neuroendocrine tumors).

Product overview

Crinetics Pharmaceuticals is a global pharmaceutical company with its first commercial product PALSONIFY (paltusotine), an oral SST2 agonist approved for acromegaly. The company has a deep pipeline of 10+ disclosed programs including atumelnant (oral ACTH antagonist in Phase 3 for CAH and Phase 1/2b for Cushing's syndrome) and CRN09682 (nonpeptide drug conjugate for neuroendocrine tumors in Phase 1/2). Additional discovery programs target TSH, PTH, SST3, GH, GLP-1, and GIP receptors. The company also offers digital health tools including the Acromegaly Symptom Diary mobile app and patient support programs through CrinetiCARE.

Differentiator

Problem solved

Functional benefit

Products and services

• PALSONIFY (paltusotine) A selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist; the first and only once-daily, oral therapy approved by FDA and EMA for the treatment of adults with acromegaly who had inadequate response to surgery and/or for whom surgery is not an option. Also in Phase 3 development for carcinoid syndrome associated with neuroendocrine tumors.
• Atumelnant (CRN04894) The first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. In development for classic congenital adrenal hyperplasia (Phase 3 CALM-CAH trial) and ACTH-dependent Cushing's syndrome (Phase 1/2b trial).
• CRN09682 A nonpeptide drug conjugate candidate being developed to treat somatostatin receptor 2 (SST2) expressing neuroendocrine tumors and other SST2-expressing solid tumors. Currently in Phase 1/2 clinical trial.
• CrinetiCARE Patient support program for PALSONIFY, offering enrollment through specialty pharmacies (Orsini, Biologics) and direct dispenses from pituitary treatment centers. Includes free IGF-1 testing resources for patients.
• Acromegaly Symptom Diary Mobile App A mobile application designed to help individuals with acromegaly track and notice potential breakthrough symptoms. Part of the Everyday Advocacy initiative to support patient self-advocacy in healthcare interactions.

Quantifiable outcome

• 93% of PATHFNDR-1 participants maintained stable IGF-1 levels (0.81x ULN at 96 weeks)
• +6 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Acromegaly CommunitycoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in Crinetics' Everyday Advocacy initiative steering committee. The initiative provides educational resources, support tools, and community connections for people living with acromegaly and other endocrine conditions.
• CARES FoundationcoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization for congenital adrenal hyperplasia participating in the Everyday Advocacy steering committee. CARES Foundation provides expertise on patient needs for CAH management and advocacy.
• Cushing's Support & Research FoundationcoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in the Everyday Advocacy initiative steering committee, focusing on supporting people living with Cushing's syndrome and related conditions.
• Neuroendocrine Cancer FoundationcoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in the Everyday Advocacy steering committee, providing support and resources for patients with neuroendocrine cancers and related conditions.
• Pituitary World NewscoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in the Everyday Advocacy steering committee, focused on pituitary disease awareness and support for patients and caregivers.
• Ohio UniversityminorStrategic or Co-development Partner · 7 May 2026Crinetics entered into an exclusive license agreement with Ohio University in May 2026 to develop an early preclinical growth hormone receptor antagonist for the treatment of acromegaly. This partnership expands Crinetics' pipeline of endocrine therapies.
• Orsini HealthcarecoreChannel Partner/ Reseller/ Distributor · 26 September 2025Orsini Healthcare was selected by Crinetics as the specialty pharmacy partner for PALSONIFY (paltusotine). PALSONIFY represents the first once-daily oral treatment approved for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. The therapy is the fifth therapy to join Orsini's Endocrinology Center of Excellence, expanding patient access to this rare disease treatment.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Recordati: Recordati acquired Chiasma and markets Mycapssa, the other approved oral acromegaly therapy. Recordati is a direct competitor in the same patient population with a directly competing oral SST2-targeting product, making it the most directly comparable peer to Crinetics in the acromegaly franchise.
• Ipsen: Ipsen markets Somatuline (lanreotide), a leading injectable somatostatin analog for acromegaly and neuroendocrine tumors. Ipsen is a direct incumbent competing for the same patient population that PALSONIFY targets with its oral, once-daily alternative.
• Neurocrine Biosciences: Neurocrine markets Crenessity (crinecerfont), an approved therapy for classic congenital adrenal hyperplasia, directly competing with Crinetics' atumelnant in the same CAH indication. Neurocrine is also broadly focused on endocrinology, making it one of the most directly comparable peers across Crinetics' pipeline.
• Camurus: Camurus markets octreotide depot formulations for acromegaly and neuroendocrine tumors, competing in the same SST2-targeting space as PALSONIFY and paltusotine. Camurus is a more focused direct peer as a specialty pharmaceutical company with deep somatostatin agonist expertise.

Broad incumbents

• Novartis: Novartis markets Sandostatin (octreotide), the long-standing injectable somatostatin analog standard of care for acromegaly and NETs, and acquired AAA for Lutathera radioligand therapy. Novartis is a broad incumbent with overlapping capabilities but a much larger portfolio spanning many therapeutic areas.
• Pfizer: Pfizer markets Somavert (pegvisomant), a growth hormone receptor antagonist used in acromegaly patients who fail first-line therapy. Pfizer is a broad incumbent offering a mechanistically distinct alternative for the same acromegaly population that Crinetics serves with PALSONIFY.

Emerging players

• Ascendis Pharma: Ascendis Pharma is an endocrinology-focused rare disease company with TransCon hGH (Lonapegsomatropin) and other endocrine programs. While not directly competing in acromegaly or CAH, Ascendis is a peer in the broader rare endocrine specialty pharmaceutical space with similar commercial-stage dynamics.
• Amryt Pharma (Chiesi Farmaceutici): Amryt Pharma, now part of Chiesi, had a presence in acromegaly and other rare endocrine disorders. It is an emerging player with overlapping rare endocrine focus but narrower portfolio compared to Crinetics' broader endocrine pipeline.
• Theratechnologies: Theratechnologies markets Egrifta (tesamorelin) for HIV-associated lipodystrophy and has development programs in acromegaly. It is an emerging peer with partial overlap in the rare endocrine space served by Crinetics.
• Soleno Therapeutics: Soleno Therapeutics is focused on rare endocrine disorders including Prader-Willi syndrome, with an approved therapy in that space. While not a direct acromegaly competitor, Soleno is comparable as a small-cap commercial-stage rare endocrine pharmaceutical company.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Crinetics
• YouTubeyoutube.com/@crineticspharmaceuticals
• Facebookfacebook.com/Crinetics
• LinkedInlinkedin.com/company/crinetics-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds17 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crinetics Pharmaceuticals